Akebia Therapeutics Inc (FRA:AX9)
€ 1.642 0.149 (9.98%) Market Cap: 359.71 Mil Enterprise Value: 368.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Akebia Therapeutics Inc to Host Stockholder Information Session Transcript

Apr 21, 2023 / 12:00PM GMT
Release Date Price: €0.593 (-9.05%)
Mercedes Carrasco
Akebia Therapeutics, Inc. - Director of Corporate Communications

Good morning, and welcome to Akebia's Stockholder Information Session. Today, I'm joined by John Butler, Akebia's CEO; and Dave Spellman, CFO.

Before we begin, I'd like to remind everyone that this webcast includes forward-looking statements. Each forward-looking statement on this webcast is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in Risk Factors and Management Discussion and Analysis section of our most recent annual and quarterly reports filed with the SEC. The forward-looking statements on this webcast speak only as to the original date of the webcast, and, except as required by law, we do not undertake any obligation to update or revise these statements.

On March 17, we filed a revised definitive proxy statement with the SEC in connection with a special meeting of stockholders now scheduled to reconvene on May 4, 2023 at 10 a.m. Eastern Time in a virtual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot